FDA Initiatives To Expedite Reviews Pay Off In FY’11 Approvals

By Bridget Silverman / Email the Author / Pharmaceutical Approvals Monthly November 2011, Vol. 16, No. 11
New Drug Approvals / Word Count: 1226 / Article # 06111101027

Executive Summary

A report released on the 35 innovative drug approvals in the fiscal year touts the role of many FDA initiatives in speeding and streamlining drug development and approval.

Purchase this Article

$85.00 Buy Now

For $85.00, purchase this 1226-word article and receive immediate online access. 100% Satisfaction Guarantee.

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: FDA Initiatives To Expedite Reviews Pay Off In FY’11 Approvals

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to Pharmaceutical Approvals Monthly will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

FDA Initiatives To Expedite Reviews Pay Off In FY’11 Approvals

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 5

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article